HIV-1 vector systems
- PMID: 12465462
- DOI: 10.1023/a:1021074613196
HIV-1 vector systems
Abstract
Human immunodeficiency virus type 1 (HIV-1) based gene transfer systems are gaining in popularity due to their ability to transduce terminally differentiated and non-dividing cells. Oncoretroviral vectors based on Moloney murine leukemia virus (MoMLV), on the other hand, can only transduce dividing cells. The reasons for increased ability of lentivirus vectors to transduce such cells has been attributed to several of the viral proteins (integrase, matrix and Vpr) that are purported to be involved in the nuclear import of the pre-integration complex (PIC). Nuclear import is also augmented by a unique triple stranded DNA region created during reverse transcription of the incoming viral RNA in the target cell (discussed in chapter 3). This chapter deals with the rationale behind the design of human immunodeficiency virus type 1 (HIV-1) based packaging systems with an emphasis on some recent advances in the field for the creation of safe and efficient HIV-1 based vectors. The review covers trans-acting proteins and cis-sequences required for the deployment of HIV-1 vectors for gene transfer. This is a rapidly advancing field that with further refinements may soon allow the utilization of HIV-1 based and/or other lentivirus vectors in a clinical setting.
Similar articles
-
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences.Nat Genet. 2000 Jun;25(2):217-22. doi: 10.1038/76095. Nat Genet. 2000. PMID: 10835641
-
Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer.Methods. 2004 Jun;33(2):164-72. doi: 10.1016/j.ymeth.2003.11.005. Methods. 2004. PMID: 15121171
-
Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.Gene Ther. 1995 Nov;2(9):639-46. Gene Ther. 1995. PMID: 8548553
-
Retroviral vectors for gene therapy of AIDS and cancer.Curr Opin Mol Ther. 2001 Oct;3(5):468-75. Curr Opin Mol Ther. 2001. PMID: 11699891 Review.
-
Lentiviral vectors and gene therapy.Front Biosci. 1999 Jun 1;4:D481-96. doi: 10.2741/klimatcheva. Front Biosci. 1999. PMID: 10352135 Review.
Cited by
-
Viral Vectors in Gene Therapy.Diseases. 2018 May 21;6(2):42. doi: 10.3390/diseases6020042. Diseases. 2018. PMID: 29883422 Free PMC article. Review.
-
Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.Mol Ther. 2009 Apr;17(4):632-40. doi: 10.1038/mt.2009.299. Epub 2009 Jan 27. Mol Ther. 2009. PMID: 19174762 Free PMC article.
-
Substitution of the Rev-response element in an HIV-1-based gene delivery system with that of SIVmac239 allows efficient delivery of Rev M10 into T-lymphocytes.AIDS Res Ther. 2008 Jun 5;5:11. doi: 10.1186/1742-6405-5-11. AIDS Res Ther. 2008. PMID: 18534033 Free PMC article.
-
Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.Hum Gene Ther Methods. 2018 Feb;29(1):1-15. doi: 10.1089/hgtb.2017.098. Epub 2018 Jan 24. Hum Gene Ther Methods. 2018. PMID: 29212357 Free PMC article.
-
Refinement of lentiviral vector for improved RNA processing and reduced rates of self inactivation repair.BMC Biotechnol. 2009 Oct 7;9:86. doi: 10.1186/1472-6750-9-86. BMC Biotechnol. 2009. PMID: 19811661 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources